Investing.com — Shares of Guardant Health rose 5.0% in pre-market trading Tuesday, following the company’s announcement that its Guardant Reveal test for colon cancer received Medicare coverage enlarged.
The company reported that Palmetto GBA, a Medicare administrative contractor, has expanded coverage of the test. This now allows the monitoring of disease recurrence in patients with colorectal cancer (CRC) who have undergone treatment with curative intent.
The company said this development marks an expansion from previous Medicare coverage. Previously, Medicare coverage for the Guardant Reveal test was limited to CRC screening only in the early postsurgical setting.
-The expansion of coverage now allows more complete monitoring of patients with CRC.
This article was generated and translated with the help of AI and reviewed by an editor. For more information, see our T&Cs.
